转甲状腺素蛋白淀粉样变性中的心肌淀粉样负荷
本研究纳入1541例接受心脏磁共振(CMR)的转甲状腺素蛋白淀粉样变性(ATTR)受试者,定义细胞外容积(ECV)校准阈值并评估其诊断与预后价值。ECV<30%可排除、≥40%可确认心脏受累,30%-39%提示早期浸润;ECV独立预测全因死亡(每增加10%,HR 1.22,95%CI 1.10-1.34,P<0.001)。ECV可直接量化心肌淀粉样负荷,为ATTR分期和治疗规划提供定量框架。
要点
- ECV<30%排除心脏受累,≥40%确认,30%-39%提示早期浸润。
- ECV每增加10%,全因死亡风险独立增加22%(HR 1.22)。
- ECV分层(<30%、30%-39%、40%-49%、50%-59%、≥60%)显示风险单调递增。
核心结论
- ECV直接量化心肌淀粉样负荷,并首次定义可重复的阈值以分层负荷并细化风险预测,超越分期、生物标志物和影像。
- ECV为ATTR淀粉样变性的分期和治疗规划提供了定量框架。
研究设计与样本
- 研究纳入1541例因ATTR接受CMR的受试者,分为TTR变异携带者(n=123)、心外ATTR(n=41)、早期ATTR-CM(n=70)或明确ATTR-CM(n=1,308)。
- 终点为全因死亡。
主要发现
- ECV在携带者和心外ATTR中相似,但从早期阶段到ATTR-CM升高。
- ECV与生物标志物、NAC分期、Perugini分级和超声心动图指标的关联 modest,重叠广泛。
- 中位随访2.8年(IQR 1.4-4.3年)期间,612例(40%)死亡。
- 多变量分析后,ECV独立预测死亡率(每增加10%,HR 1.22;95%CI 1.10-1.34;P<0.001)。
- 按ECV分类(无<30%;轻度30%-39%;中度40%-49%;中重度50%-59%;重度≥60%)分层显示风险单调增加。
关键数值与推荐
- ECV<30%排除心脏受累,≥40%确认心脏受累,30%-39%提示早期浸润。
- ECV预后价值在hs-troponin和NT-proBNP分层、Perugini 1-3级和LVMI三分位中均保留,低生物标志物/低LVMI分层梯度更陡。
临床怎么用
- 临床可使用CMR-ECV阈值(<30%、30%-39%、≥40%)诊断和分期心脏受累。
- ECV分层(<30%至≥60%)可用于风险预测和治疗规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stabilizers/silencers limit new transthyretin amyloid formation, whereas emerging agents aim to clear existing deposits. Cardiovascular magnetic resonance (CMR) extracellular volume (ECV) reflects myocardial amyloid and may provide a quantitative framework for therapeutic planning OBJECTIVES: The aim was to define calibrated ECV thresholds, evaluate their diagnostic and prognostic value, and explore how CMR-ECV could provide a quantitative framework for disease staging and therapeutic planning. METHODS: We studied 1,541 subjects undergoing CMR for transthyretin amyloidosis (ATTR) classified as TTR-variant carriers (n = 123), extracardiac ATTR (n = 41), early-stage ATTR-CM (n = 70), or overt ATTR-CM (n = 1,308). The endpoint was all-cause mortality. RESULTS: ECV was similar in carriers and extracardiac ATTR but rose from early-stage to ATTR-cardiomyopathy (CM). Associations with biomarkers, National Amyloidosis Centre (NAC) stage, Perugini grade, and echocardiographic measures were modest, with wide overlap. Diagnostic performance was excellent: ECV <30% excluded and ≥40% confirmed cardiac involvement, whereas 30% to 39% indicated early infiltration. Over a median follow-up of 2.8 years (IQR: 1.4-4.3 years), 612 patients (40%) died. Prognostically, ECV independently predicted mortality (HR: 1.22 per 10% increase; 95% CI: 1.10-1.34 per 10% increase; P < 0.001) after multivariable analysist. Stratifying patients by ECV categories (degree of infiltration: none <30%; mild = 30%-39%; moderate = 40%-49%; moderate-to-severe = 50%-59%; severe ≥60%) showed monotonic risk increase across categories. ECV retained prognostic value across hs-troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strata, Perugini grades 1 to 3, and left ventricular mass index (LVMI) tertiles, with steeper gradients in low-biomarker/low-LVMI strata. CONCLUSIONS: ECV directly quantifies myocardial amyloid load and, for the first time, defines reproducible thresholds that stratify burden and refine risk prediction beyond stage, biomarkers, and imaging, providing a quantitative framework for staging and therapeutic planning in ATTR amyloidosis.
引用
- Sheikh A, Achten A, Aimo A, et al. Myocardial Amyloid Burden in Transthyretin Amyloidosis. J Am Coll Cardiol. 2025. PMID: 41369616. doi:10.1016/j.jacc.2025.10.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。